Urol. praxi. 2021;22(2):83-87 | DOI: 10.36290/uro.2021.018

Mamingomyelocele as seen by a urologist

MUDr. Zdeněk Dítě, FEAPU1, 3, 4, MUDr. Matúš Bašovský2
1 Urologická klinika 1. LF UK a VFN Praha
2 Oddělení dětské neurologie, Fakultní Thomayerova nemocnice, Praha
3 MEDICINA PLUS Ambulance, s. r. o., Praha
4 TH klinika, Praha

Myelomeningocele is one of the forms of spina bifida and described as a sac containing fluid and a neural tissue protruded from the back. It occurs when there is an incomplete closure of the spinal cord during the first month of pregnancy, most frequently in lumbosacral area. Afflicted children can be at high risk of urinary tract complication connected with neurogennic urinary bladder. Renal failure remains one of the most common causes of mortality in patients with spina bifida. Hence, to prevent the occurrence of neurogenic bladder and renal damage, a full urological examination and treatment after birth and continuous long-life urological care should be obtained.

Keywords: meningomyelocele, spina bifida, neurogennic bladder, renal failure.

Received: April 5, 2021; Revised: May 2, 2021; Accepted: May 2, 2021; Prepublished online: May 2, 2021; Published: June 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dítě Z, Bašovský M. Mamingomyelocele as seen by a urologist. Urol. praxi. 2021;22(2):83-87. doi: 10.36290/uro.2021.018.
Download citation

References

  1. Nethi S. Aryia K. Meningocele - StatPearls - NCBI Bookshelf (nih.gov), https://www.ncbi.nlm.nih.gov/books/NBK562174, 10, 2020.
  2. Volpe J, et al. Neurology of the newborn. Philadelphia: Elsevier 2018: 1224 s.
  3. Šípek A, et al. Spina bifida v české republice - incidence a prenatální diagnostika. Cesk Slov Neurol. 2019; 82(4): 410-414. Go to original source...
  4. De Jong TPVM, Chrzan R, Klijn AJ. Treatment of the neurogenic bladder in spina bifida. Pediatr. Nefrol. 2008; 23: 889-896. Go to original source... Go to PubMed...
  5. Stein R, Bogaert G, Dogan HS, et al. EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescents part I diagnostics and conservative treatment. Neurourology and Urodynamics 2019; 1-13. Go to original source... Go to PubMed...
  6. Kessler TM, Lackner J, Kiss G, Madersbacher H. Early proactive management improve upper urinary tract function and reduces the need for surgery in patients with meningomyelocele. Neurourol Urodyn. 2006; 25: 758-762. Go to original source... Go to PubMed...
  7. Bauer SB. Neurogenic bladder: etiology and assesment. Pediatr Nephrol. 2007; 23: 541-551. Go to original source... Go to PubMed...
  8. Scholtmeijer RJ, van Maastrigt R. The effect of oxyphenonium bromid and oxybutinin hydrochloride on detrusor contractlity and reflux in children with vesicoureteral reflux and detrusor instability. J. Urol. 1991; 146: 660-662. Go to original source... Go to PubMed...
  9. Humphreys MR, Reinberg YE. Contemporary and emerging drug treatments for urinary incontinence in children. Pediatr. Drugs 2005; 7(3): 151-162. Go to original source...
  10. Hoebeke PB, Van de Walle J. The pharmacology of pediatric incontinence. B. J. U. 2000; 86: 581-589. Go to original source... Go to PubMed...
  11. Bolduc S, Moore K, Nadeau G, et al. Prospective open label study of solifenacin for overactive bladder in children. J. Urol 2010; 184: 1668-1673. Go to original source... Go to PubMed...
  12. Rawashdeh YF, Austin P, Siggard C, et al. International Children´s Continence Society´s recomenndations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012; 31: 615-620. Go to original source... Go to PubMed...
  13. Austin PF, Homsy YL, Masel JL, et al. Alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. J Urol. 1999 Sep; 162(3 Pt 2): 1064-1067. Go to original source... Go to PubMed...
  14. Dítě Z, Kočvara R. Intravezikální instilace propiverinu v léčbě neurogenních dysfunkcí močového měchýře. Urol. praxi 2012; 13: 264-266.
  15. Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia 1991; 29: 84-90. Go to original source... Go to PubMed...
  16. Nadeau G, Schroder A. Double anticholinergic therapy for refractory neurogenic and non-neurogenic detrusor overactivity in children: Longterm results of a prospective open-label study. Can. Urol. Assoc. J. 2014; 8: 175-180. Go to original source... Go to PubMed...
  17. Chapple CR, Cardoso L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety and tolerability. Neurourol Urodyn. 2014; 33: 17-30. Go to original source... Go to PubMed...
  18. Fryer S, Nicoara C, Dobson E, et al. Effectiveness and tolerability of mirabegron in children with overactive bladder: a retrospective pilot study. J Pediatr Surg. 2020; 55: 316-318. Go to original source... Go to PubMed...
  19. Blais AS, Nadeau G, Moore K, et al. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Eur. Urol. 2016; 70: 9-13. Go to original source... Go to PubMed...
  20. Morin F, Blais AS, Nadeau G, et al. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol. 2017; 197: 1158-1163. Go to original source... Go to PubMed...
  21. Austin PF, Homsy YL, Masel JL, et al. α-adrenergic blockade in children with neuropathic and nonneuropathic voiding. J. Urol. 1999; 162: 1064-1067. Go to original source... Go to PubMed...
  22. Hanuš T. Intermitentní katetrizace močového měchýře. Čas. Lék. čes. 1983; 37: 1135-1137.
  23. Kaefer M, Pabby A, Kelly M, et al. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with meningomyelocele. J. Urol. 1999; 162: 1068-1071. Go to original source... Go to PubMed...
  24. Dyer L, Franco I. Botulinum toxin-A therapy in pediatric urology: indications for the neurogenic and non-neurogenic neurogenic bladder. ScientificWorld Journal 2009; 9: 1300-1305. Go to original source... Go to PubMed...
  25. Zerhau P, Husár M. Použití Botulotoxinu v dětské urologii. Urol. Praxi 2019; 20: 9-12. Go to original source...
  26. Akil I, Ozen C, Cengiz B. Do patients with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis? Turk. J. Med.Sci. 2016; 46: 1151-1154. Go to original source... Go to PubMed...
  27. Seki N, Masuda K, Kinukawa N, et al. Risk factors for febrile urinary tract infection in children with myelodysplasia treated by clean intermittent catheterisation. Int. J. Urol. 2004; 11: 973-977. Go to original source... Go to PubMed...
  28. Overgoor ML, Kon M, Cohen-Kettenis PT, et al. Neurological bypass for sensory inervation of penis in patients with spina bifida. J. Urol. 2006; 176: 1086-1090. Go to original source... Go to PubMed...
  29. Wood D, Baird A, Carmignani L, et al. Lifelong congenital urology: the challenges for patients and surgeons. Eur. Urol. 2019; 75: 1001-1007. Go to original source... Go to PubMed...
  30. Kovell RC, Skokan AJ, Wood DN. Transitional Urology. Urol Clin North Am. 2018; 45: 601-610. Go to original source... Go to PubMed...
  31. Dítě Z. Tranziční péče o pacienty s neurogenním měchýřem od puberty do dospělosti. Ces Urol 2018; 22(3): 159-163.




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.